Press Releases

Initiator Pharma A/S (“Initiativtagaren” eller “Bolaget”) offentliggör utfallet i Bolagets företrädesemissionen vars teckningstid avslutades den 26 juni 2025. Utfallet visar att 6 133 159 aktier, motsvarande cirka 43,7 procent av Företrädesemissionen, tecknades med stöd av teckningsrätter. Härutöver tecknades 277 458 aktier, motsvarande cirka 2,0 procent av Företrädesemissionen, utan stöd av teckningsrätter. 5 670 164 aktier, motsvarande cirka 40,4 procent av Företrädesemissionen, tecknades med stöd av emissionsgarantier. Företrädesemissionen kommer att tillföra Bolaget cirka 48,3 MSEK före före emissionskostnader.

Initiator Pharma A/S (“Initiator” or the “Company”) announces the outcome of the Company’s rights issue of up to 14,039,590 shares (the “Rights Issue”), for which the subscription period ended on 26 June 2025. In the Rights Issue, 6 133 159 shares, corresponding to around 43.7 percent of the Rights Issue were subscribed through subscription rights. Additionally, 277 458 shares, corresponding to around 2.0 percent of the Rights Issue were subscribed without subscription rights. 5 670 164 shares, corresponding to around 40,4 percent of the Rights Issue were subscribed through guarantee undertakings. The Rights Issue will provide the Company with proceeds of approximately SEK 48.3 million before deduction of costs related to the Rights Issue.

Company reg. (CVR) no. 37663808

Initiator Pharma updates the timeline for the rights issue, the record date is on June 10, 2025 and the subscription period runs from and including June 12, 2025 up to and including June 26, 2025.

Initiator Pharma uppdaterar tidplanen för företrädesemissionen, avstämningsdagen är den 10 juni 2025 och teckningsperioden löper från och med den 12 juni 2025 till och med den 26 juni 2025.

The annual general meeting of Initiator Pharma A/S (reg. no. 37663808 the “Company”) was held at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE on 23 May 2025 at 10.00 AM CEST.

Company reg. (CVR) no. 37663808

The board of directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today, based on the authorisation from the general meeting held on 24 May 2024, resolved on a new issue of shares with pre-emption rights for the Company’s existing shareholders amounting to approximately SEK 56.2 million before issue costs (the “Rights Issue”). The Company has received subscription commitments from existing shareholders, including Linc and MAC Clinical Research, as well as members of the board of directors and management, amounting to approximately SEK 15 million, corresponding to approximately 27 percent of the Rights Issue. The Company has furthermore entered into guarantee undertakings with existing shareholders and external investors which, in aggregate, amount to approximately SEK 33 million, corresponding to approximately 59 percent of the Rights Issue. Consequently, the Rights Issue is covered by subscription commitments and guarantee undertakings amounting to approximately SEK 48 million, corresponding to approximately 86 percent of the Rights Issue.